Main results
This review includes three RCTs (two PD and one CD). The PD-RCTs employed disparate units of randomisation (UofR); patient or transfusion, while the CD-RCT applied the patient as the UofR. The PD-RCTs administered leukodepleted blood products. Both PD-RCTs compared acetaminophen plus diphenhydramine (ApD) at different regimens with placebo, while the CD-RCT contrasted hydrocortisone pharmacotherapy with diphenhydramine. Both PD-RCTs found no statistically significant difference in allergic reactions (RR 0.13, 95% confidence interval (CI) 0.01 to 2.39, RR 1.46, 95% CI 0.78 to 2.73) and febrile reactions (RR 0.52, 95% CI 0.22 to 1.26). The CD-RCT found a statistically significant difference in the odds of febrile reactions (OR 2.38, 95% CI 1.07 to 5.27). The trials did not report anaphylactic reactions, deaths related to transfusion reactions or other adverse events.
Authors' conclusions
None of the three studies found that medication prior to transfusion reduces NHTR. This applied regardless of the patient's history of NHTR and the use of leukodepleted blood products in the transfusion. However, this conclusion is based on three trials of moderate to low quality. A better-powered RCT is necessary to evaluate the role of pretransfusion medication in the prevention of NHTR. Inclusion criteria should be restricted to patients at high risk of developing NHTR, with no restriction by age, history of transfusion reactions and type of blood products (leukodepleted or not).
P L A I N L A N G U A G E S U M M A R Y

Pre-transfusion drugs for preventing side effects from blood transfusions
Febrile non-haemolytic transfusion reactions (FNHTRs) and allergic reactions are the most common adverse reactions to blood transfusion. These reactions are often related to other dangerous side effects from transfusion such as sepsis due to contaminated blood products and intravascular red cell haemolysis.
In an effort to prevent these reactions, patients are given drugs prior to transfusion. Three kinds of drugs are commonly used for this pre-transfusion medication, either alone or in combination. However, this practice is not standardised and there is controversy about its effectiveness.
This review found that current evidence from three trials in which 462 patients were analysed indicates pre-transfusion medication in any regimen does not reduce the risk of allergic and febrile non-haemolytic transfusion reactions. 
Medium risk population
Adverse events
Study population RR 0 (0 to 0) 0 (Geiger 2007; Heddle 1999) . Although these adverse transfusion events are usually not associated with serious clinical sequelae (Perrotta 2001) or a reduction in the effectiveness of the transfusion (Sarkodee-Adoo 1998), the high rate of reactions in patients transfused with pooled platelet concentrate or non-leukoreduced blood components has led to the practice of pre-transfusion medication in an attempt to reduce reaction rates. This pre-transfusion medication can involve acetaminophen (paracetamol), alone or in combination with diphenhydramine, or hydrocortisone (glucocorticoid).
Description of the intervention
Acetaminophen (paracetamol) is a non-steroidal anti-inflammatory drug with potent antipyretic and analgesic properties but with very weak anti-inflammatory properties (Botting 2000) . The main toxicity of acetaminophen is liver damage. The common dose of this drug is 650 mg for adults and 10 mg/kg for children (Geiger 2007 
Why it is important to do this review
There is controversy about the use of pre-transfusion medication. Febrile and allergic transfusion reactions are rare in children and patients transfused with leukoreduced, irradiated blood products whether or not they have received pre-transfusion medication (Sanders 2005) . In adults, one study suggested that pre-transfusion medication provides significant advantages for patients but that its use does not yield significant cost benefits for the healthcare provider (Ezidiegwu 2004). One randomised controlled trial did not find clinical effectiveness in preventing non-haemolytic reactions (Wang 2002) . Two papers (Geiger 2007 and Tobian 2007) found no evidence to support pre-transfusion medication as a clinical approach in the prevention of transfusion reactions. Therefore, the aim of this Cochrane review is to answer the following clinical question: 'What is the efficacy and safety of pretransfusion medications for preventing allergic and febrile nonhaemolytic transfusion reactions?'.
O B J E C T I V E S
To determine, for patients with and without a history of transfusion reactions, whether pharmacological interventions:
• are effective in preventing allergic and febrile nonhaemolytic transfusion reactions, and death;
• are safe; and
• differ in their efficacy or safety.
M E T H O D S
Criteria for considering studies for this review Types of studies Both published and unpublished RCTs were included.
Types of participants
Any patient requiring a blood transfusion. Participants could be of any age or sex, could be treated in any setting and could have cancer, haematologic malignancies, non-haematologic malignancies and require a chronic transfusion regimen.
Types of interventions
Only pharmacological interventions were considered. Trials could compare different pre-transfusion approaches or different doses and routes of administration for the same pre-transfusion. Transfusions with whole blood or blood components were considered.
Types of outcome measures
Primary outcomes
1. Febrile reactions (fever with or without chills, chills with or without rigors).
2. Allergic reactions (urticaria with or without pruritus). 3. Anaphylactic reactions (dyspnoea, wheezing, hypotension, tachycardia, loss of consciousness, shock).
4. Death related to transfusion reactions. 5. Other adverse events.
Search methods for identification of studies
We did not restrict the searches by date, language or publication status.
Electronic searches
We searched the following electronic databases: Supplementary searches of the Web using the Internet search engines Google (www.google.co.uk/) and Google scholar (www.scholar.google.co.uk/) were used to identify grey literature and authors in this field. Bibliographies of relevant trials were searched for additional material and to identify additional authors. Authors were contacted directly to identify information on completed and ongoing trials.
Data collection and analysis
Selection of studies
Each reference identified by the searches was independently checked by two review authors (Arturo Martí-Carvajal (AMC) and Luís E. González (LEG)) against the agreed inclusion criteria. Disagreements were resolved through discussion and Ivan Solà (IS) was consulted on any discrepancies.
Data extraction and management
Data extraction was carried out by two review authors (AMC and LEG) using a pre-designed data extraction form containing publication type, details such as patient population, randomisation, allocation concealment, details of blinding measures, description of interventions and results (Zavala 2006). Discrepancies were resolved through discussion or by consulting a third author (IS). Data were entered into Review Manager software (RevMan 2008) and IS checked for accuracy.
Assessment of risk of bias in included studies
This section describes the recommended approach for assessing risk of bias in trials included in Cochrane reviews (Higgins 2009). Three authors (AMC, IS, LEG) independently assessed each included trial for risk of bias in six domains:
• Methods used to generate the allocation sequence.
• Concealment of allocation.
• Blinding (clinician, participant, outcome assessor).
• Incomplete outcome data.
• Selective outcome reporting.
• Other sources of bias.
A judgement was reached relating to the risk of bias by answering a pre-specified question about the adequacy of the study in relation to each of these domains. A judgement of 'Yes' indicated low risk of bias, 'No' indicated high risk of bias, and 'Unclear' indicated unclear or unknown risk of bias (Higgins 2009). The detailed risk of bias assessment is included in the Characteristics of included studies table. Studies were grouped in to two categories: low risk of bias (when the allocation concealment was adequate and double blind) and high risk of bias (for all other scenarios).
Measures of treatment effect
For dichotomous data, we presented results as summary risk ratios with 95% confidence intervals. Because one of the included studies used a cross-over design (Wang 1992), we used the BeckerBalagtas marginal estimated odds ratio (OR) to summarise the transfusion reactions outcomes (Elbourne 2002). Wang 1992 used a cross-over design and the patient as its unit of analysis. We used statistical methodology guidelines suggested by Elbourne 2002 to analyse data from this trial.
Unit of analysis issues
Dealing with missing data
For all outcome analyses that were carried out on an intentionto-treat (ITT) basis, we attempted to include all participants randomised to each group. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. We did contact the main author of each RCT in an attempt to obtain these missing data. We did ITT analysis by using the imputation method (worst-case scenario versus best-case scenario).
Assessment of heterogeneity
This review did not include meta-analysis. For future updates, we will use the I 2 statistic to measure heterogeneity among the trials in each analysis. I 2 describes the percentage of total variation across studies due to heterogeneity rather than sampling error (Higgins 2003) . If substantial heterogeneity (I² > 50%) is identified we will explore it by prespecified subgroup analysis.
Assessment of reporting biases
Where reporting bias was suspected, study authors were contacted and asked to provide absent outcome data. Where this was not possible, and the missing data thought to introduce serious bias, the impact of including such studies in the overall assessment of results was explored by sensitivity analysis. For future updates, we will also attempt to assess whether the review is subject to publication bias by using a funnel plot.
Data synthesis
Statistical analysis was carried out using Review Manager software (RevMan 2008) and Comprehensive Meta-analysis® version 2. Despite this Cochrane review containing three randomised controlled trials (Kennedy 2008; Wang 1992; Wang 2002) , data was not pooled due to heterogeneity of pharmacotherapy and methodology. In subsequent updates, we will use random-effects model meta-analysis for combining data where trials are examining the same intervention, and the trials' populations and methods are judged sufficiently similar.
Subgroup analysis and investigation of heterogeneity
In subsequent updates of this review, when sufficient data are available, we plan to carry out the following subgroup analyses:
1. Leukoreduced blood products versus non-leukoreduced blood products.
2. Type of blood products (platelet concentrate, packed red cell, platelet rich plasma).
3. Patients with history of NHTR versus patients without history of NHTR.
4. Type or types of drug used for preventing allergic and febrile non-haemolytic reactions.
5. Type of disorder (non-haematological, haematological malignancies, and non-haematological malignancies). The following outcomes will be used in subgroup analysis:
2. Mild allergic reactions (urticaria with or without pruritus). 3. Anaphylatic reactions (dyspnoea, wheezing, hypotension, tachycardia, loss of consciousness, or shock).
4. Death related to transfusion reactions. 5. Other adverse events. For random-effects meta-analyses we will assess differences between subgroups by inspection of their confidence intervals; where non-overlapping confidence intervals indicate a statistically significant difference in treatment effect between the subgroups.
Sensitivity analysis
In subsequent updates we also plan to conduct a sensitivity analysis comparing the results using all studies and using only those of high methodological quality.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification. We identified 148 references from our search strategy, of which 134 were excluded as irrelevant after examining the title and abstract. Full text copies of the remaining 14 references were obtained for more detailed examination.
Included studies
Three randomised controlled trials (RCTs) published between 1992 and 2008 met inclusion criteria, giving a total of 462 participants for analysis (Wang 1992; Wang 2002; Kennedy 2008) . A detailed description of the included trials is provided in the Characteristics of included studies table. The trials varied in the following characteristics: pre-transfusion randomisation, participant population, study design, pre-transfusion medication composition, study country, blood product transfusion, history of transfusion reaction, measures of treatment effect, sample size and duplicate publication. All three RCTs were at moderate risk of bias. 
Pre-transfusion medication randomisation
Study design
Two studies were conducted using parallel study design (Kennedy 2008; Wang 2002) , and one used a crossover design (Wang 1992).
Pre-transfusion medication composition
Two RCTs used acetaminophen (500 or 650 mg per oral) and diphenhydramine (25 mg IV) as pre-transfusion for preventing transfusion reactions (Kennedy 2008; Wang 2002) . Wang 1992 used small doses of hydrocortisone (50 mg IV) plus diphenhydramine (40 mg IV) as pharmacotherapy preventing transfusion reaction. It was classified as " hives with or without itching".
Study country
---- 
Studies ongoing and pending publication
The search did not identify any ongoing studies.
Studies awaiting classification
The search found one study (Ricevuti 1984) which is awaiting classification. Attempts were made to contact its main author but no reply was received. See Studies awaiting classification.
Risk of bias in included studies
The 
Effects of interventions
Primary outcomes (1) Febrile reactions (fever with or without chills, chills with or without rigors).
• Acetaminophen plus diphenhydramine versus placebo (Kennedy 2008 , Wang 2002 The trials included in the review showed no difference between febrile reaction rates when comparing acetaminophen plus diphenhydramine with placebo.
Kennedy 2008 (315 participants; 21 events) showed a non-significant risk ratio for febrile reactions (RR 0.52, 95% CI 0.22 to 1.26 -see Analysis 1.1). Similarly, Wang 2002 (98 transfusions; 12 events) showed that the risk ratio for febrile reactions was statistically non-significant when comparing acetaminophen plus diphenhydramine with placebo (RR 1.77, 95% CI 0.57 to 5.49 -see Analysis 2.1).
• Diphenhydramine versus hydrocortisone Wang 1992 (73 randomised participants, 146 participants for paired analysis, 116 beneficial events) showed that patients treated with hydrocortisone had a lower rate of febrile reactions compared to those treated with diphenhydramine (OR 2.38, 95% CI 1.07 to 5.26). Table 2 shows raw data from Wang 1992. , and all those with missing outcomes in the placebo group had 'normal' outcomes) and the best-case scenario (all participants with missing outcomes in the intervention group had 'normal' outcomes, and all those with missing outcomes in the placebo group had 'febrile reactions') were: RR worstscenario 1.96 (95% CI 0.90 to 4.27) for febrile reactions and RR bestscenario 0.32 (95% CI 0.74 to 0.72) for febrile reactions -see Analysis 1.1. Sensitivity analyses of allergic reactions to account for the 19 excluded patients showed discrepancy on this outcome. According to Kennedy 2008 et al, the RRs for the worst-case scenario (all participants with missing outcomes in the intervention group had 'allergic reactions', and all those with missing outcomes in the placebo group had 'normal' outcomes) and the best-case scenario (all participants with missing outcomes in the intervention group had 'normal' outcomes, and all those with missing outcomes in the placebo group had 'allergic reactions') were: RR worstscenario 1.34 (95% CI 0.82 to 2.18) for allergic reactions and RR bestscenario 1.90 (95% CI 0.72 to 5.02) allergic reactions -see Analysis 1.2.
• Wang 2002
The 24 transfusions excluded by this study could not be included in an ITT analysis because we were unable to determine their transfusion allocation group. The study author was contacted for this information but we received no reply. Sensitivity analyses of non-haemolytic transfusion reactions (fever) to account for the 24 excluded transfusions showed discrepancy on this outcome. According to Wang 2002, the RRs for the worstcase scenario (all participants with missing outcomes in the intervention group had 'febrile reactions', and all those with missing outcomes in the placebo group had 'normal' outcomes) and the best-case scenario (all participants with missing outcomes in the intervention group had 'normal' outcomes, and all those with missing outcomes in the placebo group had 'febrile reactions') were:
RR worstscenario 7.08 (95% CI 2.71 to 18.50) for febrile reactions and RR bestscenario 0.25 (95% CI 0.13 to 0.50) febrile reactionssee Analysis 2.1.
Sensitivity analyses of allergic reaction (hives) to account for the 24 excluded transfusions showed discrepancy on this outcome. According to Wang 2002, the RRs for the worst-case scenario (all participants with missing outcomes in the intervention group had 'allergic reactions', and all those with missing outcomes in the placebo group had 'normal' outcomes) and the best-case scenario (all participants with missing outcomes in the intervention group had 'normal' outcomes, and all those with missing outcomes in the placebo group had 'allergic reactions') were: RR worstscenario 7.08 (95% CI 2.28 to 21.97) for allergic reactions and RR bestscenario 0.02 (95% CI 0.00 to 0.26) allergic reactions -see Analysis 2.2. 
Acetaminophen plus
Medium risk population
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
D I S C U S S I O N
Summary of main results
This review of pharmacological interventions for preventing allergic and febrile non-haemolytic transfusion reactions included three randomised controlled trials whose critical assessment does not support the clinical use of these interventions. We did not find significant differences on incidence of febrile reactions (fever with or without chills, chills with or without rigors), mild allergic reactions (urticaria with or without pruritus). The data from the included studies (462 participants) is inconclusive. Randomised controlled trials differed somewhat in the following characteristics: pre-transfusion randomisation, participant population, study design, pre-transfusion medication composition, study country, blood product transfusion, history of transfusion reaction, measures of treatment effect, sample size and duplicate publication.
Overall completeness and applicability of evidence
The main limitation of this Cochrane review was the impossibility of pooling the results into a meta-analysis. However, this is explained by several clinical and methodological differences in the included RCTs (Wang 1992; Wang 2002; Kennedy 2008) that prevented a pooled analysis. Although the incidence of transfusion reactions from these RCTs was low, these studies included patients with or without history of transfusion reactions, leading to incomplete data and no definitive conclusion. All included RCTs were conducted using less than 500 patients.
Quality of the evidence
The review authors' assessment of the risk of bias of the included studies has been described previously and a summary can be found in Figure 1 and Figure 2 . The studies were at moderate risk of bias.
Potential biases in the review process
Publication bias represents a major threat to the validity of systematic reviews. We aimed to minimise bias by completing an exhaustive search which included many clinical trial registries. however it was a retrospective review without a control group. The review included 120,000 units of transfused blood products, 80% of which were preceded by pre-transfusion. The main target of this study was determining the cost implications of pre-transfusion medications, and while it found pre-transfusion reduced reaction rates, this did not provide a significant cost benefit to the healthcare provider.
Agreements and disagreements with other studies or reviews
A U T H O R S ' C O N C L U S I O N S Implications for practice
We found no evidence that pre-transfusion medication prevents NHTR. This applies regardless of the patient's history of NHTR and whether or not they were transfused with leukodepleted blood products. This conclusion is based on three trials with moderate risk of bias. Practically, this implies the prescription of pre-transfusion medication is not justified, unless new evidence from a large high quality trial modifies this conclusion.
Implications for research
A powerful RCT is necessary to effectively evaluate the role of pretransfusion medication. Inclusion criteria should only involve patients with high risk of developing febrile, allergic or anaphylactic reactions. There should be no restriction by history of transfusion reactions, age, type of blood products used (leukodepleted or not) and pre-transfusion transfusion safety. Trials should be structured and reported according to the 'Consort Statement' checklist to improve the quality of findings with the aim to standardise patient management.
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Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Unclear Quote: "Patients were assigned to the placebo or the active treatment with equal probability using blocked randomisation" (Page 2286). 
D E C L A R A T I O N S O F I N T E R E S T
In 2004 Arturo Martí-Carvajal was employed by Eli Lilly to run a four hour workshop on 'how to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.
In 2007 Arturo Martí-Carvajal was employed by Merck to run a four hour workshop 'how to critically appraise clinical trials and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.
Other authors: none.
S O U R C E S O F S U P P O R T
